Does BENDAMUSTINE Cause Diffuse large b-cell lymphoma recurrent? 255 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 255 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with BENDAMUSTINE (VIVIMUSTA). This represents 1.3% of all adverse event reports for BENDAMUSTINE.
255
Reports of Diffuse large b-cell lymphoma recurrent with BENDAMUSTINE
1.3%
of all BENDAMUSTINE reports
71
Deaths
54
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From BENDAMUSTINE?
Of the 255 reports, 71 (27.8%) resulted in death, 54 (21.2%) required hospitalization, and 15 (5.9%) were considered life-threatening.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BENDAMUSTINE. However, 255 reports have been filed with the FAERS database.
What Other Side Effects Does BENDAMUSTINE Cause?
Off label use (2,578)
Disease progression (2,456)
Pyrexia (1,322)
Neutropenia (1,256)
Drug ineffective (1,135)
Febrile neutropenia (1,005)
Pneumonia (975)
Thrombocytopenia (967)
Covid-19 (892)
Anaemia (817)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which BENDAMUSTINE Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
BENDAMUSTINE vs BENDROFLUMETHIAZIDE
BENDAMUSTINE vs BENIDIPINE
BENDAMUSTINE vs BENLYSTA
BENDAMUSTINE vs BENRALIZUMAB
BENDAMUSTINE vs BENSERAZIDE